Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Drug Delivery System, ISSN 0913-5006, 2018, Volume 33, Issue 4, pp. 318 - 328
Journal Article
ISSN 0913-5006, 01/2018, Volume 33, Issue 4, p. 318
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 1, pp. 1 - 10
The liposome, a closed phospholipid bilayered vesicular system, has received considerable attention as a pharmaceutical carrier of great potential over the...
gene therapy | theranostics | PEGylation | drug delivery system | liposome | immunotherapy | Liposome | Gene therapy | Drug delivery system | Theranostics | Immunotherapy | DRUG-DELIVERY | ANTISENSE OLIGODEOXYNUCLEOTIDES | LARGE UNILAMELLAR LIPOSOMES | ANTITUMOR-ACTIVITY | TRIGGERED RELEASE | TUMOR-TARGETED DELIVERY | PH-SENSITIVE LIPOSOMES | IN-VIVO | PHARMACOLOGY & PHARMACY | SOLID TUMOR | LIPID-COMPOSITION | Liposomes - chemistry | Liposomes - therapeutic use | Animals | Humans | Drug Delivery Systems | Biodegradation | Drugs | Drug delivery systems | Biodegradability | Phospholipids | Pharmacology | Drug delivery | Hydrophobicity | Drug development | Chemical compounds | Optimization | Design optimization | Biocompatibility | Liposomes | System effectiveness
gene therapy | theranostics | PEGylation | drug delivery system | liposome | immunotherapy | Liposome | Gene therapy | Drug delivery system | Theranostics | Immunotherapy | DRUG-DELIVERY | ANTISENSE OLIGODEOXYNUCLEOTIDES | LARGE UNILAMELLAR LIPOSOMES | ANTITUMOR-ACTIVITY | TRIGGERED RELEASE | TUMOR-TARGETED DELIVERY | PH-SENSITIVE LIPOSOMES | IN-VIVO | PHARMACOLOGY & PHARMACY | SOLID TUMOR | LIPID-COMPOSITION | Liposomes - chemistry | Liposomes - therapeutic use | Animals | Humans | Drug Delivery Systems | Biodegradation | Drugs | Drug delivery systems | Biodegradability | Phospholipids | Pharmacology | Drug delivery | Hydrophobicity | Drug development | Chemical compounds | Optimization | Design optimization | Biocompatibility | Liposomes | System effectiveness
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 1, pp. 1 - 10
The liposome, a closed phospholipid bilayered vesicular system, has received considerable attention as a pharmaceutical carrier of great potential over the...
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 2008, Volume 354, Issue 1, pp. 56 - 62
We and a Dutch group reported that “empty” PEGylated liposomes (approximately 100 nm) lose their long-circulating characteristic when they are administrated...
Complement activation | Liposomes | Repeated injection | Polyethylene glycol (PEG) | IgM | Accelerated blood clearance (ABC) phenomenon | ADVANCED HEPATOCELLULAR-CARCINOMA | accelerated blood clearance (ABC) phenomenon | STERICALLY STABILIZED LIPOSOMES | liposomes | REFRACTORY OVARIAN | OVARIAN-CANCER | polyethylene glycol (PEG) | complement activation | PHYSICOCHEMICAL PROPERTIES | PHASE-II TRIAL | CIRCULATION TIME | PROTEIN ADSORPTION | POLY(ETHYLENE GLYCOL) | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | repeated injection | Animals | Injections, Intravenous | Complement Activation | Drug Administration Schedule | Liposomes - administration & dosage | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Drug Carriers - pharmacokinetics | Immunoglobulin M - immunology | Liposomes - pharmacokinetics | Polyethylene Glycols - administration & dosage | Liposomes - immunology | Polyols | Immunoglobulins | Television broadcasting industry
Complement activation | Liposomes | Repeated injection | Polyethylene glycol (PEG) | IgM | Accelerated blood clearance (ABC) phenomenon | ADVANCED HEPATOCELLULAR-CARCINOMA | accelerated blood clearance (ABC) phenomenon | STERICALLY STABILIZED LIPOSOMES | liposomes | REFRACTORY OVARIAN | OVARIAN-CANCER | polyethylene glycol (PEG) | complement activation | PHYSICOCHEMICAL PROPERTIES | PHASE-II TRIAL | CIRCULATION TIME | PROTEIN ADSORPTION | POLY(ETHYLENE GLYCOL) | METASTATIC BREAST-CANCER | PHARMACOLOGY & PHARMACY | repeated injection | Animals | Injections, Intravenous | Complement Activation | Drug Administration Schedule | Liposomes - administration & dosage | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Drug Carriers - pharmacokinetics | Immunoglobulin M - immunology | Liposomes - pharmacokinetics | Polyethylene Glycols - administration & dosage | Liposomes - immunology | Polyols | Immunoglobulins | Television broadcasting industry
Journal Article
Methods in Molecular Biology, ISSN 1064-3745, 2019, Volume 1943, pp. 333 - 346
For the systemic application of nucleic acids [plasmid DNA (pDNA) and small interfering RNA (siRNA)], safe and efficient carriers that overcome the poor...
Anti-PEG IgM | Enzyme-linked immunosorbent assay (ELISA) | Polyethylene glycol (PEG) | Accelerated blood clearance (ABC) phenomenon | PEGylated nanocarrier
Anti-PEG IgM | Enzyme-linked immunosorbent assay (ELISA) | Polyethylene glycol (PEG) | Accelerated blood clearance (ABC) phenomenon | PEGylated nanocarrier
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 400, pp. 223 - 231
Abstract Metronomic chemotherapy is currently considered an emerging therapeutic option in clinical oncology. S-1, an oral formulation of Tegafur (TF), a...
Hematology, Oncology and Palliative Medicine | RNAi | PEG-coated shRNA-lipoplex | Short hairpin RNA | Thymidylate synthase | S-1 | Colorectal cancer | THERAPEUTICS | DIHYDROPYRIMIDINE DEHYDROGENASE | RNA-INTERFERENCE | CHEMOTHERAPY | LUNG-CANCER | ONCOLOGY | GASTRIC-CANCER | IN-VIVO | EXPRESSION LEVELS | TUMOR-GROWTH | THYMIDINE PHOSPHORYLASE | Administration, Metronomic | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Male | Antimetabolites, Antineoplastic - administration & dosage | Colorectal Neoplasms - therapy | Transfection | RNA Interference | Time Factors | Antimetabolites, Antineoplastic - metabolism | Oxonic Acid - metabolism | Colorectal Neoplasms - enzymology | Thymidylate Synthase - metabolism | Oxonic Acid - administration & dosage | Thymidylate Synthase - genetics | RNAi Therapeutics - methods | Xenograft Model Antitumor Assays | Animals | Tegafur - metabolism | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Tegafur - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | Colorectal Neoplasms - pathology | Drug Combinations | Chemotherapy | RNA | Cancer | Polyethylenes | 5-Fluorouracil | Toxicity | Tegafur | Lung cancer | Colorectal carcinoma | Metastasis | Kinases | Drug resistance | Cancer therapies | Metastases | Anticancer properties | Proteins | Polyethylene glycol | Xenografts | Chemical synthesis | Drug dosages | Dosing | RNA-mediated interference | Gene expression | Ribonucleic acid--RNA | Antitumor activity | Combined treatment | Viral infections | Apoptosis | Index Medicus
Hematology, Oncology and Palliative Medicine | RNAi | PEG-coated shRNA-lipoplex | Short hairpin RNA | Thymidylate synthase | S-1 | Colorectal cancer | THERAPEUTICS | DIHYDROPYRIMIDINE DEHYDROGENASE | RNA-INTERFERENCE | CHEMOTHERAPY | LUNG-CANCER | ONCOLOGY | GASTRIC-CANCER | IN-VIVO | EXPRESSION LEVELS | TUMOR-GROWTH | THYMIDINE PHOSPHORYLASE | Administration, Metronomic | Apoptosis - drug effects | Colorectal Neoplasms - genetics | Humans | Male | Antimetabolites, Antineoplastic - administration & dosage | Colorectal Neoplasms - therapy | Transfection | RNA Interference | Time Factors | Antimetabolites, Antineoplastic - metabolism | Oxonic Acid - metabolism | Colorectal Neoplasms - enzymology | Thymidylate Synthase - metabolism | Oxonic Acid - administration & dosage | Thymidylate Synthase - genetics | RNAi Therapeutics - methods | Xenograft Model Antitumor Assays | Animals | Tegafur - metabolism | Tumor Burden - drug effects | Mice, Nude | Cell Line, Tumor | Tegafur - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | Colorectal Neoplasms - pathology | Drug Combinations | Chemotherapy | RNA | Cancer | Polyethylenes | 5-Fluorouracil | Toxicity | Tegafur | Lung cancer | Colorectal carcinoma | Metastasis | Kinases | Drug resistance | Cancer therapies | Metastases | Anticancer properties | Proteins | Polyethylene glycol | Xenografts | Chemical synthesis | Drug dosages | Dosing | RNA-mediated interference | Gene expression | Ribonucleic acid--RNA | Antitumor activity | Combined treatment | Viral infections | Apoptosis | Index Medicus
Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 400, pp. 232 - 242
Abstract The therapeutic concept of administering chemotherapeutic agents continuously at lower doses, relative to the maximum tolerated dose (MTD) without...
Hematology, Oncology and Palliative Medicine | Nanoparticles | Tumor priming | Maximum tolerated dose | Liposomes | Dosing schedule | Metronomic chemotherapy | ADVANCED HEPATOCELLULAR-CARCINOMA | PEGYLATED LIPOSOMAL DOXORUBICIN | LOW-DOSE CYCLOPHOSPHAMIDE | STEM-LIKE CELLS | ONCOLOGY | ACCELERATED BLOOD CLEARANCE | METASTATIC BREAST-CANCER | COATED CATIONIC LIPOSOMES | RECURRENT OVARIAN-CANCER | COLORECTAL TUMOR-MODEL | ENDOTHELIAL GROWTH-FACTOR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Neoplasms - blood supply | Drug Carriers | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Maximum Tolerated Dose | Animals | Neoplasms - immunology | Nanomedicine - methods | Drug Compounding | Neoplasms - pathology | Angiogenesis Inhibitors - adverse effects | Angiogenesis Inhibitors - chemistry | Drugs | Antimitotic agents | Chemotherapy | Drug delivery systems | Pharmacy | Drugstores | Development and progression | Antineoplastic agents | Cancer | Vehicles | CD8 antigen | Cytotoxicity | Metastasis | Drug resistance | Cancer therapies | Blood | Anticancer properties | Metastases | Angiogenesis | Breast carcinoma | Bone marrow | CD25 antigen | Inhibition | Drug dosages | Antigens | Macromolecules | Blood vessels | Exposure | Ablation | Carriers | Inhibitors | Surveillance | Antigen-presenting cells | Stem cells | Angiogenesis inhibitors | Accessibility | Toxicity | Dormancy | Lymphocytes | Modulation | Immune system | Effectiveness | Tumor cells | Vessels | Pharmacology | Breast cancer | Inflammation | Permeability | CD4 antigen | Hypotheses | Cell death | Antigen (tumor-associated) | Breast | Antitumor activity | Microenvironments | Cations | Pharmacokinetics | Tumors | Apoptosis | Index Medicus
Hematology, Oncology and Palliative Medicine | Nanoparticles | Tumor priming | Maximum tolerated dose | Liposomes | Dosing schedule | Metronomic chemotherapy | ADVANCED HEPATOCELLULAR-CARCINOMA | PEGYLATED LIPOSOMAL DOXORUBICIN | LOW-DOSE CYCLOPHOSPHAMIDE | STEM-LIKE CELLS | ONCOLOGY | ACCELERATED BLOOD CLEARANCE | METASTATIC BREAST-CANCER | COATED CATIONIC LIPOSOMES | RECURRENT OVARIAN-CANCER | COLORECTAL TUMOR-MODEL | ENDOTHELIAL GROWTH-FACTOR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Neoplasms - blood supply | Drug Carriers | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Maximum Tolerated Dose | Animals | Neoplasms - immunology | Nanomedicine - methods | Drug Compounding | Neoplasms - pathology | Angiogenesis Inhibitors - adverse effects | Angiogenesis Inhibitors - chemistry | Drugs | Antimitotic agents | Chemotherapy | Drug delivery systems | Pharmacy | Drugstores | Development and progression | Antineoplastic agents | Cancer | Vehicles | CD8 antigen | Cytotoxicity | Metastasis | Drug resistance | Cancer therapies | Blood | Anticancer properties | Metastases | Angiogenesis | Breast carcinoma | Bone marrow | CD25 antigen | Inhibition | Drug dosages | Antigens | Macromolecules | Blood vessels | Exposure | Ablation | Carriers | Inhibitors | Surveillance | Antigen-presenting cells | Stem cells | Angiogenesis inhibitors | Accessibility | Toxicity | Dormancy | Lymphocytes | Modulation | Immune system | Effectiveness | Tumor cells | Vessels | Pharmacology | Breast cancer | Inflammation | Permeability | CD4 antigen | Hypotheses | Cell death | Antigen (tumor-associated) | Breast | Antitumor activity | Microenvironments | Cations | Pharmacokinetics | Tumors | Apoptosis | Index Medicus
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 5, pp. 665 - 674
A 2% commercially available, milky-white, rebamipide micro-particle suspension is used to treat dry eyes, and it causes short-term blurring of the patient's...
Journal Article
Composites Science and Technology, ISSN 0266-3538, 04/2016, Volume 127, pp. 1 - 7
In this paper, the effectiveness of lightning damage suppression by a carbon-fiber-reinforced polymer (CFRP) laminate with a newly developed polyaniline...
Mechanical properties (B) | Lightning damage | Conductive thermosetting composite | Electrical properties (B) | Thermal properties (B) | MATERIALS SCIENCE, COMPOSITES | COMPOSITES | Crosslinked polymers | Electrical conductivity | Polymer industry | Laminated materials | Epoxy resins | Electric properties | Polymer matrix composites | Simulation | Electrical resistivity | Lightning | Resistivity | Carbon fiber reinforced plastics | Thermosetting resins | Damage
Mechanical properties (B) | Lightning damage | Conductive thermosetting composite | Electrical properties (B) | Thermal properties (B) | MATERIALS SCIENCE, COMPOSITES | COMPOSITES | Crosslinked polymers | Electrical conductivity | Polymer industry | Laminated materials | Epoxy resins | Electric properties | Polymer matrix composites | Simulation | Electrical resistivity | Lightning | Resistivity | Carbon fiber reinforced plastics | Thermosetting resins | Damage
Journal Article
Biological & Pharmaceutical Bulletin, ISSN 0918-6158, 06/2013, Volume 36, Issue 6, p. 889
In contrast to the general assumption that polyethyleneglycol (PEG)-conjugated substances lack immunogenicity and antigenic, it has been reported that they...
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 7, pp. 1078 - 1083
Modulation of tumor immunity is a known factor in the antitumor activity of many chemotherapeutic agents. Exosomes are extracellular nanometric vesicles that...
chemotherapeutic agent | doxorubicin | exosome | splenectomy | liposomal doxorubicin | Liposomal doxorubicin | Splenectomy | Chemotherapeutic agent | Exosome | Doxorubicin | RESPONSES | SPLEEN | EXTRACELLULAR VESICLES | PHARMACOLOGY & PHARMACY | RELEASE | CELL-DERIVED EXOSOMES | CHEMOTHERAPY | Spleen | Size distribution | CD9 antigen | Intravenous administration | CD63 antigen | Secretion | Injection | Secretions | Exosomes | Immunity | Immunosuppressive agents | Anticancer properties | Time dependence | Vesicles | Chemotherapy | Antitumor agents | Antitumor activity | Mice | In vivo methods and tests | Cancer | Tumors | Immune system
chemotherapeutic agent | doxorubicin | exosome | splenectomy | liposomal doxorubicin | Liposomal doxorubicin | Splenectomy | Chemotherapeutic agent | Exosome | Doxorubicin | RESPONSES | SPLEEN | EXTRACELLULAR VESICLES | PHARMACOLOGY & PHARMACY | RELEASE | CELL-DERIVED EXOSOMES | CHEMOTHERAPY | Spleen | Size distribution | CD9 antigen | Intravenous administration | CD63 antigen | Secretion | Injection | Secretions | Exosomes | Immunity | Immunosuppressive agents | Anticancer properties | Time dependence | Vesicles | Chemotherapy | Antitumor agents | Antitumor activity | Mice | In vivo methods and tests | Cancer | Tumors | Immune system
Journal Article
Biological & Pharmaceutical Bulletin, ISSN 0918-6158, 05/2013, Volume 36, Issue 5, p. 692
Nanocarrier-based cancer chemotherapeutics are thought to increase therapeutic efficiency and reduce the side effects of associated chemotherapeutic agents...
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 11/2013, Volume 172, Issue 1, pp. 38 - 47
Despite the clinical introduction of an increasing number of polyethylene glycol (PEG)-conjugated substances, PEG has been named as the cause of an unexpected...
Anti-PEG IgM | Polyethylene glycol(PEG) | Repeated administration | Accelerated blood clearance (ABC) phenomenon | Splenic B cells | Accelerated blood clearance (ABC) | phenomenon | PEGYLATED LIPOSOMAL DOXORUBICIN | IMMUNE-RESPONSE | COVALENT ATTACHMENT | MARGINAL ZONE | PEG IgM | ANTITUMOR-ACTIVITY | REPEATED INJECTION | CHEMISTRY, MULTIDISCIPLINARY | PEG | PHARMACOKINETICS | POLY(ETHYLENE GLYCOL) | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | Anti | Spleen - immunology | Complement Activation | Humans | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Immunoglobulin M - immunology | Drug Carriers - chemistry | Polyethylene Glycols - administration & dosage | Liposomes - chemistry | Animals | Immunoglobulin M - blood | Liposomes - blood | Liposomes - immunology | Polyols | Television broadcasting industry | B cells | Polyethylene glycol | Pharmacy | Blood
Anti-PEG IgM | Polyethylene glycol(PEG) | Repeated administration | Accelerated blood clearance (ABC) phenomenon | Splenic B cells | Accelerated blood clearance (ABC) | phenomenon | PEGYLATED LIPOSOMAL DOXORUBICIN | IMMUNE-RESPONSE | COVALENT ATTACHMENT | MARGINAL ZONE | PEG IgM | ANTITUMOR-ACTIVITY | REPEATED INJECTION | CHEMISTRY, MULTIDISCIPLINARY | PEG | PHARMACOKINETICS | POLY(ETHYLENE GLYCOL) | PHARMACOLOGY & PHARMACY | POLYETHYLENE-GLYCOL | Anti | Spleen - immunology | Complement Activation | Humans | Drug Carriers - administration & dosage | Polyethylene Glycols - chemistry | Immunoglobulin M - immunology | Drug Carriers - chemistry | Polyethylene Glycols - administration & dosage | Liposomes - chemistry | Animals | Immunoglobulin M - blood | Liposomes - blood | Liposomes - immunology | Polyols | Television broadcasting industry | B cells | Polyethylene glycol | Pharmacy | Blood
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 5, pp. 733 - 742
Exosomes are tiny extracellular vesicles that are usually harvested in small quantities. Such small yield has been an obstacle for the expansion of the basic...
exosome secretion | PEGylation | cationic lipid | liposome | stimulation | Liposome | Stimulation | Exosome secretion | Cationic lipid | DENSITY | DRUG-DELIVERY | IN-VIVO | NANOPARTICLE | MICROVESICLES | PHARMACOLOGY & PHARMACY | LIPOSOMES | Formulations | Biological properties | Drug delivery systems | Tumor cells | Secretion | Drug delivery | Tumor cell lines | Exosomes | Vesicles | Cations | Yield | Liposomes | Physicochemical properties | Tumors
exosome secretion | PEGylation | cationic lipid | liposome | stimulation | Liposome | Stimulation | Exosome secretion | Cationic lipid | DENSITY | DRUG-DELIVERY | IN-VIVO | NANOPARTICLE | MICROVESICLES | PHARMACOLOGY & PHARMACY | LIPOSOMES | Formulations | Biological properties | Drug delivery systems | Tumor cells | Secretion | Drug delivery | Tumor cell lines | Exosomes | Vesicles | Cations | Yield | Liposomes | Physicochemical properties | Tumors
Journal Article
Cancer Science, ISSN 1347-9032, 09/2017, Volume 108, Issue 9, pp. 1864 - 1869
Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we...
immunomodulation | Antitumor immunity | oxaliplatin | drug delivery system | liposome | TUMOR-MODEL | MECHANISM | ONCOLOGY | SUPPRESSOR-CELLS | CANCER | CHEMOTHERAPY | Neoplasm Transplantation | Immunologic Factors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Histocompatibility Antigens Class I - metabolism | Organoplatinum Compounds - administration & dosage | Animals | Colorectal Neoplasms - immunology | Mice, Nude | Colorectal Neoplasms - drug therapy | Cell Line, Tumor | Mice, Inbred BALB C | Liposomes | Drug Screening Assays, Antitumor | Drugs | Drug delivery systems | Chemotherapy | Colorectal cancer | T cells | Health aspects | Tumors | Vehicles | Cancer | Encapsulation | Peptides | CD8 antigen | Colorectal carcinoma | Cytotoxicity | Lymphocytes T | Macrophages | Suppressor cells | Cancer therapies | Oxaliplatin | Lymphocytes | Polyethylene glycol | Immunotherapy | Drug dosages | Immunoregulation | Immunomodulation | Tumor cells | Immunodeficiency | Studies | Major histocompatibility complex | Antitumor activity | Original
immunomodulation | Antitumor immunity | oxaliplatin | drug delivery system | liposome | TUMOR-MODEL | MECHANISM | ONCOLOGY | SUPPRESSOR-CELLS | CANCER | CHEMOTHERAPY | Neoplasm Transplantation | Immunologic Factors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Histocompatibility Antigens Class I - metabolism | Organoplatinum Compounds - administration & dosage | Animals | Colorectal Neoplasms - immunology | Mice, Nude | Colorectal Neoplasms - drug therapy | Cell Line, Tumor | Mice, Inbred BALB C | Liposomes | Drug Screening Assays, Antitumor | Drugs | Drug delivery systems | Chemotherapy | Colorectal cancer | T cells | Health aspects | Tumors | Vehicles | Cancer | Encapsulation | Peptides | CD8 antigen | Colorectal carcinoma | Cytotoxicity | Lymphocytes T | Macrophages | Suppressor cells | Cancer therapies | Oxaliplatin | Lymphocytes | Polyethylene glycol | Immunotherapy | Drug dosages | Immunoregulation | Immunomodulation | Tumor cells | Immunodeficiency | Studies | Major histocompatibility complex | Antitumor activity | Original
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 9, pp. 1555 - 1558
Hydrodynamic tail vein injection was considered an in vivo transfection method that yields a higher level of gene expression mainly in the liver. This method...
Journal Article